Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.

ABSTRACT:

Background

Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a common, yet unsupported practice in some countries.

Methods

We analysed outcome among all patients (n=99) who received subsequent therapy after progression on one of five consecutive, single-arm, phase II clinical trials evaluating bevacizumab regimens for recurrent glioblastoma. Of note, the five trials contained similar eligibility, treatment and assessment criteria, and achieved comparable outcome.

Results

The median overall survival (OS) and OS at 6 months for patients who c

SUBMITTER: Reardon DA 

PROVIDER: S-EPMC3493761 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature